It is a highly effective biological agent that is widely used in rheumatism treatment.
Rheumatism is a chronic, systematic, self-immunological disease characterized by symmetrical, multi-coastal inflammation that can cause joint pain, swelling, malformations and functional loss, which seriously affects the quality of life and ability to work of patients. Traditional rheumatist drugs, such as ammonium butterflies, may have some therapeutic effects, but some patients are either poorly responding or unable to withstand their side effects. The emergence of the Adam stand-alone resistance has given new hope to such patients.
The single-activation mechanism of Adawood is mainly to disrupt the combination of TNF-α with TNF receptors on the surface of the cell, by combining tumour necrosis in the human body – alpha (TNF-α), thereby inhibiting a series of inflammatory reactions by TNF-α. TNF-α plays a key role in the onset of rheumatism arthritis, which promotes the activation, multiplication and immersion of inflammation cells, induces the growth of membrane cells and vascular formations, and thereby erodes joint cartilage and bone tissue. The Adam standoff has been effective in reducing TNF-α’s local and systemic adverse effects on the joints.
In terms of improving the symptoms of the joints of patients, most patients suffer from rapid reduction in the pain and swelling of the joints following the use of the Adawood monolithic system, with a marked reduction in the morning rigidity. In clinical settings, most patients experience a marked decline in joint pain and swelling in the weeks following treatment, as well as a significant increase in mobility, which allows them to better carry out activities in their daily lives, such as walking, grabbing, etc.
From the point of view of the progress of the disease, the single resistance of Adam can effectively slow down and even prevent the destruction of the joints of rheumatism. Long follow-up visits have found that the incidence of narrow joint faults and bone damage among patients who continue to receive single anti-treatment at Adam is significantly lower than for patients who have not used or used traditional medications to be ineffective and who have not converted to treatment programmes. This means that not only will the anti-Adam monolithic symptoms be mitigated, but it will also protect joint structures and functions in the long term and reduce the risk of disability.
In terms of improving the quality of life of patients, as a result of the reduction of joint symptoms and control of the progress of the disease, the quality of their sleep has improved, their emotional state has become more stable, and their social activities and working abilities have gradually been restored. Their ability to re-engage in normal family life, social interaction and professional work greatly reduces the psychological and social stress associated with illness.
Of course, Adawood resistance is not without risk in its use. It may increase the likelihood of infection, such as respiratory infections, skin infections, etc., and may cause adverse reactions such as local reaction in the injection area. Therefore, in the use of the Adam monotherapy for rheumatism arthritis, doctors are required to critically assess the patient ‘ s condition, physical condition and complications, to monitor closely the adverse effects of the treatment, and to cooperate with regular laboratory examinations and video assessments to ensure the effectiveness and safety of the treatment.
On the whole, Adam is a very effective drug in the treatment of rheumatism, providing better treatment options for a large number of patients, with excellent performance in improving symptoms, controlling the progress of the disease and improving the quality of life, subject to appropriate application under professional medical supervision.
